Medicare Enrolled
Dr. Daniel Kobrinski, D.O.
Internal Medicine · Neptune Beach, FL
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Kobrinski from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Kobrinski? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Kobrinski
Dr. Daniel Kobrinski is an internal medicine in Neptune Beach, FL, with 14 years in practice. Based on federal Medicare data, Dr. Kobrinski performed 192,587 Medicare services across 32,197 unique beneficiaries.
Between the years covered by Open Payments, Dr. Kobrinski received a total of $7,333 from 60 pharmaceutical and/or device companies across 209 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in internal medicine. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Kobrinski is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 14 years in practice▲ Top 0% volume in FL$ $7,333 industry payments
Medicare Practice Summary
Medicare Utilization ↗192,587
Medicare services
Top 0% in FL for internal medicine
32,197
Unique beneficiaries
$10
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~13,756 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Injectafer) | 60,000 | $1 | $4 |
| Comprehensive metabolic blood panel | 20,796 | $10 | $60 |
| Pembrolizumab injection (Keytruda) | 15,000 | $43 | $108 |
| Contrast dye for imaging (iodine-based) | 9,700 | $0 | $1 |
| Iron sucrose injection (Venofer) | 7,600 | $0 | $2 |
| Flow cytometry, additional marker | 7,487 | $17 | $102 |
| Ferritin level test (iron stores) | 5,667 | $13 | $94 |
| Immunoglobulin level test | 5,591 | $9 | $39 |
| Iron binding capacity test | 5,577 | $9 | $25 |
| Iron level test | 5,576 | $6 | $30 |
| Denosumab injection (Prolia/Xgeva) | 5,040 | $18 | $39 |
| Lactate dehydrogenase (enzyme) level | 4,642 | $6 | $29 |
| Anti-nausea injection (fosaprepitant) | 4,350 | $0 | $5 |
| Magnesium level test | 4,329 | $7 | $27 |
| Epoetin alfa injection (Retacrit) for anemia | 3,340 | $6 | $27 |
| Nephelometry, test method using light | 3,164 | $13 | $35 |
| Vitamin B-12 level test | 2,933 | $15 | $104 |
| Folic acid level test | 2,338 | $14 | $101 |
| Thyroid stimulating hormone (TSH) test | 2,147 | $16 | $116 |
| Dexamethasone injection (steroid) | 1,642 | $0 | $1 |
| Blood draw (venipuncture) | 1,633 | $8 | $18 |
| Complete blood count (CBC) with differential | 1,521 | $8 | $41 |
| Carcinoembryonic antigen (cea) protein level | 1,358 | $19 | $130 |
| Phosphate level test | 1,247 | $5 | $17 |
| PSA test (prostate cancer screening) | 1,161 | $18 | $126 |
| Injection, granisetron hydrochloride, 100 mcg | 1,160 | $0 | $41 |
| Basic metabolic blood panel | 1,056 | $8 | $47 |
| Office visit, established patient (20-29 min) | 774 | $62 | $104 |
| Beta-2 microglobulin (protein) level | 707 | $16 | $111 |
| Anti-nausea injection (Aloxi/palonosetron) | 660 | $1 | $75 |
| Office visit, established patient (30-39 min) | 411 | $95 | $162 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 396 | $21 | $90 |
| Uric acid level test | 375 | $4 | $15 |
| Drug injection, under skin or into muscle | 351 | $10 | $42 |
| Flow cytometry technique for dna or cell analysis, first marker | 325 | $52 | $170 |
| Administration of chemotherapy into vein, 1 hour or less | 305 | $97 | $355 |
| Injection, zoledronic acid, 1 mg | 230 | $7 | $282 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 205 | $46 | $160 |
| Hospital follow-up visit, moderate complexity | 184 | $62 | $115 |
| Blood creatinine level | 148 | $5 | $29 |
| Injection, diphenhydramine hcl, up to 50 mg | 96 | $1 | $4 |
| Ct scan of chest with contrast | 88 | $48 | $500 |
| Injection of additional new drug or substance into vein | 79 | $11 | $55 |
| Administration of chemotherapy into vein, each additional hour | 79 | $21 | $80 |
| Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | 78 | $70 | $70 |
| CT scan of abdomen and pelvis with contrast | 75 | $165 | $538 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 73 | $1 | $7 |
| Testosterone (hormone) level, total | 71 | $25 | $55 |
| Infusion into a vein for hydration, each additional hour | 64 | $10 | $40 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 60 | $15 | $45 |
| New patient office visit (30-44 min) | 58 | $81 | $181 |
| Infusion into a vein for hydration, 31-60 minutes | 49 | $25 | $130 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 47 | $14 | $55 |
| Blood potassium level | 44 | $5 | $28 |
| Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | 44 | $66 | $151 |
| Infusion, normal saline solution , 1000 cc | 42 | $2 | $97 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 40 | $401 | $1,000 |
| Gene analysis (calreticulin), common variants | 39 | $119 | $328 |
| Gene analysis (janus kinase 2) variant | 39 | $90 | $247 |
| Gene analysis (janus kinase 2) targeted sequence analysis | 39 | $182 | $500 |
| Gene analysis (mpl proto-oncogene, thrombopoietin receptor) for detection of common variants | 39 | $147 | $406 |
| Administration of additional new drug or substance into vein, 1 hour or less | 39 | $49 | $175 |
| Initial hospital admission, moderate complexity | 36 | $103 | $229 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 35 | $1,098 | $2,400 |
| CT scan of chest, without contrast | 32 | $44 | $310 |
| Initial hospital admission, high complexity | 23 | $137 | $330 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 21 | $1 | $21 |
| New patient office visit (45-59 min) | 18 | $126 | $265 |
| Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m servic | 14 | $10 | $30 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
31.6% high complexity
25.9% medium
42.5% routine
Industry Payment Transparency
Open Payments through 2024 ↗$7,333
Total received (2018-2024)
Avg $1,048/year across 7 years
Top 9% in FL for internal medicine
60
Companies
209
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$4,654 (63.5%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$2,600 (35.5%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$79 (1.1%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$1,094
2023$1,844
2022$237
2021$276
2020$1,386
2019$2,280
2018$214
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Adaptive Biotechnologies Corporation
$2,600
Epizyme, Inc.
$1,044
PFIZER INC.
$460
Novartis Pharmaceuticals Corporation
$392
Merck Sharp & Dohme Corporation
$221
Janssen Biotech, Inc.
$221
Foundation Medicine, Inc.
$213
Genentech USA, Inc.
$177
Takeda Pharmaceuticals U.S.A., Inc.
$159
AstraZeneca Pharmaceuticals LP
$140
Daiichi Sankyo Inc.
$136
Medtronic, Inc.
$135
GlaxoSmithKline, LLC.
$119
GENZYME CORPORATION
$112
Alexion Pharmaceuticals, Inc.
$99
Celgene Corporation
$85
BeiGene USA, Inc.
$61
Alnylam Pharmaceuticals Inc.
$53
Incyte Corporation
$48
ABBVIE INC.
$46
Acrotech Biopharma Inc.
$42
E.R. Squibb & Sons, L.L.C.
$41
Lilly USA, LLC
$38
Rigel Pharmaceuticals, Inc.
$35
Merck Sharp & Dohme LLC
$33
Dova Pharmaceuticals
$29
Coherus Biosciences Inc.
$29
Regeneron Healthcare Solutions, Inc.
$28
TESARO, Inc.
$27
Global Blood Therapeutics, Inc.
$27
Stemline Therapeutics Inc.
$26
Aurobindo Pharma USA, Inc.
$25
Taiho Oncology, Inc.
$25
Astellas Pharma US Inc
$23
Tempus AI, Inc
$22
Mirati Therapeutics, Inc.
$22
Secura Bio, Inc.
$22
Octapharma USA, Inc.
$20
ADC Therapeutics America, Inc.
$20
Bayer Healthcare Pharmaceuticals Inc.
$18
Gilead Sciences, Inc.
$18
Lexicon Pharmaceuticals, Inc.
$17
Janssen Pharmaceuticals, Inc
$16
EMD Serono, Inc.
$16
Boehringer Ingelheim Pharmaceuticals, Inc.
$15
JAZZ PHARMACEUTICALS INC.
$15
TAIHO ONCOLOGY, INC.
$13
TG Therapeutics, Inc.
$13
Sirtex Medical Inc
$13
MEDIVATION FIELD SOLUTIONS LLC
$13
Kyowa Kirin, Inc.
$13
MorphoSys, US Inc.
$13
Eisai Inc.
$12
Ipsen Biopharmaceuticals, Inc
$12
PharmaEssentia USA Corporation
$12
Bayer HealthCare Pharmaceuticals Inc.
$11
SANOFI-AVENTIS U.S. LLC
$11
ADMA BioManufacturing LLC
$9
Heron Therapeutics, Inc.
$9
Clovis Oncology, Inc.
$8
Top 3 companies account for 56.0% of total payments
Associated products mentioned in payments ›
AFINITOR · BELEODAQ · BESREMI · BOSULIF · BRAFTOVI · BRUKINSA · CABLIVI · CALQUENCE · Cinvanti · DARZALEX · Doptelet · ELIQUIS · ELREXFIO · ERLEADA · Enhertu · FARYDAK · FOUNDATIONONE · FRUZAQLA · Fabhalta · Farydak · GAZYVA · GILOTRIF · GIVLAARI · IBRANCE · IMFINZI · INJECTAFER · INLYTA · INQOVI · JAKAFI · JEVTANA · KEYTRUDA · KISQALI · KRAZATI · LENVIMA · LIBTAYO · LONSURF · LUTATHERA · LYNPARZA · Lenvima · MEKINIST · MONJUVI · MYLOTARG · NINLARO · Nubeqa · OCREVUS · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OJJAARA · OPDUALAG · OXBRYTA · Orserdu · PADCEV · PIQRAY · PLUVICTO · PROMACTA · Polivy · Poteligeo · REBLOZYL · RETEVMO · RYBREVANT · Rubraca · SANDOSTATIN · SCEMBLIX · SIR-Spheres Microspheres · SOMATULINE DEPOT · SUTENT · SYNCHROMEDII · TASIGNA · TECVAYLI · Tavalisse · Tazverik · Trodelvy · UKONIQ · ULTOMIRIS · Udenyca · Ultomiris · VENCLEXTA · VERZENIO · VPRIV · VYNDAQEL · Vanflyta · Venclexta · XARELTO · XTANDI · Xermelo · ZEJULA · ZEPZELCA · Zevalin · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (64%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians. Total industry engagement is in the top 9% for internal medicine in FL.
Equivalent to $4 per 100 Medicare services performed
Geographic Context
Internal Medicines within 10 mi
930
Per 100K population
92.3
County median income
$68,447
Nearest hospital
BAPTIST MEDICAL CENTER BEACHES
2.6 mi
2.6 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Kobrinski is a mixed practice specialist, with above-average Medicare volume (top 0% in FL), and high industry engagement (low-engagement, top 9%).
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Kobrinski experienced with iron infusion (injectafer)?
Based on Medicare claims data, Dr. Kobrinski performed 60,000 iron infusion (injectafer) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Kobrinski receive payments from pharmaceutical companies?
Yes. Dr. Kobrinski received a total of $7,333 from 60 companies across 209 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Kobrinski's costs compare to other internal medicines in Neptune Beach?
Dr. Kobrinski's average Medicare payment per service is $10. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Kobrinski) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Internal Medicines in Neptune Beach
Browse internal medicines in Neptune Beach ranked by procedure volume and transparency data.
Highest volume
Top Internal Medicines in FL
Internal Medicines ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Internal Medicines in FL
Which FL internal medicines receive the most from drug and device companies.
By company
Adaptive Biotechnologies Corporation Payments to Doctors
See all physicians who received payments from Adaptive Biotechnologies Corporation.
By company
Epizyme, Inc. Payments to Doctors
See all physicians who received payments from Epizyme, Inc..
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology